A new urine test called MyProstateScore 2.0 (MPS2) may help some men avoid unnecessary prostate biopsies. Developed by researchers at the University of Michigan, the test analyzes 18 genes linked to high-grade tumors. Negative results indicate a low likelihood of aggressive prostate cancer, reducing the need for invasive biopsies. By leveraging publicly-available databases, researchers identified genes associated with Grade Group 2 (GG2) or higher cancers, refining the test's accuracy in predicting cancer risk and guiding treatment decisions.
